GGrantIndex
← Search

CCSG Administrative Supplement for Contemporary Modifiable Exposures and Cancer Across the Cancer Control Continuum

$99,996P30FY2024CANIH

Fred Hutchinson Cancer Center, Seattle WA

Investigators

Linked publications, trials & patents

Trial NCT06995898Trial NCT06682039Trial NCT06484595Trial NCT06193070Trial NCT05947500Trial NCT05930496Trial NCT05183828Trial NCT04902144Trial NCT04751383Trial NCT04682301Trial NCT04667481Trial NCT04660331Trial NCT04539366Trial NCT04505553Trial NCT04502524Trial NCT04500548Trial NCT04496219Trial NCT04489719Trial NCT04472338Trial NCT04466475Trial NCT04447313Trial NCT04444232Trial NCT04442581Trial NCT04431479Trial NCT04410900Trial NCT04387227Trial NCT04384692Trial NCT04383743Trial NCT04375631Trial NCT04372927Trial NCT04370301Trial NCT04359784Trial NCT04336943Trial NCT04329065Trial NCT04282187Trial NCT04260776Trial NCT04257578Trial NCT04254133Trial NCT04231877Trial NCT04220229Trial NCT04211766Trial NCT04208724Trial NCT04205409Trial NCT04200482Trial NCT04198922Trial NCT04196010Trial NCT04195945Trial NCT04195633Trial NCT04194918Trial NCT04188912Trial NCT04175431Trial NCT04156828Trial NCT04155840Trial NCT04151940Trial NCT04120246Trial NCT04111497Trial NCT04083183Trial NCT04083170Trial NCT04081779Trial NCT04081298Trial NCT04062955Trial NCT04060849Trial NCT03999515Trial NCT03991884Trial NCT03986502Trial NCT03980769Trial NCT03970096Trial NCT03907527Trial NCT03891784Trial NCT03864419Trial NCT03807063Trial NCT03806192Trial NCT03781778Trial NCT03779867Trial NCT03779854Trial NCT03778021Trial NCT03776864Trial NCT03749460Trial NCT03747484Trial NCT03737955Trial NCT03723863Trial NCT03718338Trial NCT03672981Trial NCT03670966Trial NCT03670069Trial NCT03660930Trial NCT03649841Trial NCT03641287Trial NCT03606486Trial NCT03602898Trial NCT03600038Trial NCT03585231Trial NCT03574012Trial NCT03570476Trial NCT03531918Trial NCT03525106Trial NCT03523195Trial NCT03522584Trial NCT03518242Trial NCT03516812

Abstract

ABSTRACT We are pleased to submit this proposal in response to NOSI NOT-CA-24-030 - Administrative Supplements for Contemporary Modifiable Exposures and Cancer Across the Cancer Control Continuum. Microplastics (MPs), tiny plastic particles that enter the environment via the degradation of plastic waste and industrial pollution, have become a ubiquitous environmental contaminant. The presence of MPs in the oceans, drinking water, and food supply is increasingly well-documented. Accumulating evidence also demonstrates the presence of MP contamination in human tissues and biospecimens, raising significant questions as to the health implications of MP exposure and bioaccumulation. Given the ubiquity of MPs in different foods and in beverages, it is plausible that the effects of MP exposure would be especially pronounced for diseases of the colon and rectum, such as colorectal cancer (CRC). Several suggested pathways link MP exposure to CRC pathways. The presence of MPs has been implicated in triggering the production of reactive oxygen species, inducing DNA damage and an inflammatory response. Chemical additives that leach out of MPs (i.e., leachates) could also contribute to CRC pathways directly or indirectly via impacts on the gut microbiome. The objective of this proposal is to characterize the burden of MPs within the human gut, and to examine the potential implications of this burden with respect to CRC. Specifically, in Aim 1 we will quantify and contrast the burden of MPs in stool according to CRC history (1a) and in CRC tissue according to age at CRC diagnosis (1b). This latter comparison is timely given that CRC incidence rates among individuals aged <50 years have been steadily increasing over the past 30 years – consistent with the timeline of growing MP contamination. Our proposed Aim 2 allows a more mechanistic focus, where we will develop a system integrating anaerobic microbial metabolism with CRC-derived organoids to examine the host response to toxic polyvinylchloride MP leachates and to their microbial metabolites. Organoid cultures will be incubated with MP leachates and with microbial-derived metabolites of those MP leachates to assess proliferation and apoptosis, gene expression, and cancer-related pathways, yielding more detailed understanding as to the implications of MPs on the gut microbiome and CRC pathways. Production and use of plastics has increased >230-fold since 1950, meaning that each passing generation will experience greater potential for MP bioaccumulation and lifetime exposure. Given the pervasive and growing burden of MP contamination, it is critical we understand the implications of MP exposure in human populations. Through the proposed aims, this project will address a critical gap in knowledge as to the association of MP burden with CRC and will yield foundational knowledge as to the direct and indirect effects of MP exposures.

View original record on NIH RePORTER →